Literature DB >> 30032944

Symptoms of anhedonia, not depression, predict the outcome of treatment of cocaine dependence.

Paul Crits-Christoph1, Steven Wadden2, Averi Gaines2, Agnes Rieger2, Robert Gallop3, James R McKay2, Mary Beth Connolly Gibbons2.   

Abstract

The purpose of this paper is to reanalyze data from two studies to determine if anhedonia specifically, rather than depression overall, predicts treatment outcome for patients with cocaine use disorders. Measures of baseline anhedonia symptoms were created using anhedonia items from the Beck Depression Inventory (BDI) to re-examine National Institute on Drug Abuse Cocaine Collaborative Treatment study data (Crits-Christoph et al., 1999) and the contingency management group from the McKay et al. (2010) trial. Baseline anhedonia was used to predict cocaine abstinence rates across the treatment period in both studies. Anhedonia was a significant predictor of cocaine abstinence, even when overall depression scores excluding anhedonia were included in the models. The development of treatments to target individuals with cocaine use disorder who have symptoms of anhedonia has the potential to improve overall outcomes for those with this disorder.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abstinence; Anhedonia; Cocaine dependence; Depression

Mesh:

Year:  2018        PMID: 30032944      PMCID: PMC6502233          DOI: 10.1016/j.jsat.2018.06.010

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  34 in total

1.  Predicting posttreatment cocaine abstinence for first-time admissions and treatment repeaters.

Authors:  Y I Hser; V Joshi; M D Anglin; B Fletcher
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

2.  Psychosocial treatments for cocaine dependence: the role of depressive symptoms.

Authors:  Niklaus Stulz; Michael E Thase; Robert Gallop; Paul Crits-Christoph
Journal:  Drug Alcohol Depend       Date:  2011-03-01       Impact factor: 4.492

Review 3.  Neurobiology of cocaine addiction: implications for new pharmacotherapy.

Authors:  Peter W Kalivas
Journal:  Am J Addict       Date:  2007 Mar-Apr

4.  Contingency management treatments that reinforce completion of goal-related activities: participation in family activities and its association with outcomes.

Authors:  Marilyn W Lewis; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2005-03-02       Impact factor: 4.492

5.  Apathy syndrome in cocaine dependence.

Authors:  Ari D Kalechstein; Thomas F Newton; Anna H Leavengood
Journal:  Psychiatry Res       Date:  2002-01-31       Impact factor: 3.222

6.  Achieving cocaine abstinence with a behavioral approach.

Authors:  S T Higgins; A J Budney; W K Bickel; J R Hughes; F Foerg; G Badger
Journal:  Am J Psychiatry       Date:  1993-05       Impact factor: 18.112

7.  Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform.

Authors:  Joy M Schmitz; Marc E Mooney; F Gerard Moeller; Angela L Stotts; Charles Green; John Grabowski
Journal:  Drug Alcohol Depend       Date:  2007-12-27       Impact factor: 4.492

8.  Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations.

Authors:  F H Gawin; H D Kleber
Journal:  Arch Gen Psychiatry       Date:  1986-02

9.  Desipramine facilitation of initial cocaine abstinence.

Authors:  F H Gawin; H D Kleber; R Byck; B J Rounsaville; T R Kosten; P I Jatlow; C Morgan
Journal:  Arch Gen Psychiatry       Date:  1989-02

10.  Variants near CHRNB3-CHRNA6 are associated with DSM-5 cocaine use disorder: evidence for pleiotropy.

Authors:  Brooke Sadler; Gabe Haller; Arpana Agrawal; Rob Culverhouse; Kathleen Bucholz; Andy Brooks; Jay Tischfield; Eric O Johnson; Howard Edenberg; Marc Schuckit; Nancy Saccone; Laura Bierut; Alison Goate
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

View more
  8 in total

1.  Impaired frontostriatal functional connectivity among chronic opioid using pain patients is associated with dysregulated affect.

Authors:  Patrick A McConnell; Eric L Garland; Jon-Kar Zubieta; Roger Newman-Norlund; Shannon Powers; Brett Froeliger
Journal:  Addict Biol       Date:  2019-04-04       Impact factor: 4.280

2.  I feel good? Anhedonia might not mean "without pleasure" for people treated for opioid use disorder.

Authors:  Samuel W Stull; Jeremiah W Bertz; Leigh V Panlilio; William J Kowalczyk; Karran A Phillips; Landhing M Moran; Jia-Ling Lin; Massoud Vahabzadeh; Patrick H Finan; Kenzie L Preston; David H Epstein
Journal:  J Abnorm Psychol       Date:  2021-07

3.  Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder.

Authors:  Brian D Kiluk; Sarah W Yip; Elise E DeVito; Kathleen M Carroll; Mehmet Sofuoglu
Journal:  Clin Psychol Sci       Date:  2019-09-23

Review 4.  Plasticity of the Reward Circuitry After Early-Life Adversity: Mechanisms and Significance.

Authors:  Matthew T Birnie; Cassandra L Kooiker; Annabel K Short; Jessica L Bolton; Yuncai Chen; Tallie Z Baram
Journal:  Biol Psychiatry       Date:  2019-12-24       Impact factor: 13.382

Review 5.  Neural signatures of saliency-mapping in anhedonia: A narrative review.

Authors:  Angela Pisoni; Simon W Davis; Moria Smoski
Journal:  Psychiatry Res       Date:  2021-07-19       Impact factor: 11.225

6.  Physical and social anhedonia in female adolescents: A factor analysis of self-report measures.

Authors:  Xi Yang; Melynda D Casement; Kate E Keenan; Alison E Hipwell; Amanda E Guyer; Erika E Forbes
Journal:  Emotion       Date:  2021-05-31

7.  The relationship of frequency of cocaine use to substance and psychiatric disorders in the U.S. general population.

Authors:  Efrat Aharonovich; Jennifer Scodes; Melanie M Wall; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2021-07-27       Impact factor: 4.852

8.  Anhedonia and Substance Use Disorders by Type, Severity, and With Mental Health Disorders.

Authors:  Samuel W Stull; Jeremiah W Bertz; David H Epstein; Bethany C Bray; Stephanie T Lanza
Journal:  J Addict Med       Date:  2022 May-Jun 01       Impact factor: 4.647

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.